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Increased Asymmetric Dimethylarginine and Endothelin 1
Levels in Secondary Raynaud’s Phenomenon
Implications for Vascular Dysfunction and Progression of Disease
Sanjay Rajagopalan, Dana Pfenninger, Christine Kehrer, Anjan Chakrabarti, Emily Somers,
Robert Pavlic, Debabrata Mukherjee, Robert Brook, Louis G. D’Alecy, and Mariana J. Kaplan
Objective. To compare microvascular and macro-
vascular functions in a cohort of patients with primary
and secondary Raynaud’s phenomenon (RP) who were
matched for demographic, risk factor, and severity
profiles.
Methods. Forty patients with primary or second-
ary RP matched for vascular risk factors and severity
scores underwent testing of endothelial function and
cold pressor responsiveness of the brachial artery.
Microvascular perfusion of the digital vasculature was
assessed using laser Doppler fluxmetry in response to
reactive hyperemia. Plasma was assayed for endothelin
1 (ET-1), asymmetric dimethylarginine (ADMA), inter-
cellular adhesion molecule 1, vascular cell adhesion
molecule 1 (VCAM-1), and monocyte chemoattractant
protein 1 (MCP-1).
Results. Patients with RP had abnormal vasocon-
strictor responses to cold pressor tests (CPT) that were
similar in primary and secondary RP. There were no
differences in median flow-mediated and nitroglycerin-
mediated dilation or CPT of the brachial artery in the 2
populations. Patients with secondary RP were charac-
terized by abnormalities in microvascular responses to
reactive hyperemia, with a reduction in area under the
curve adjusted for baseline perfusion, but not in time to
peak response or peak perfusion ratio. Plasma ET-1,
ADMA, VCAM-1, and MCP-1 levels were significantly
elevated in secondary RP compared with primary RP.
There was a significant negative correlation between
ET-1 and ADMA values and measures of microvascular
perfusion but not macrovascular endothelial function.
Conclusion. Secondary RP is characterized by
elevations in plasma ET-1 and ADMA levels that may
contribute to alterations in cutaneous microvascular
function.
Raynaud’s phenomenon (RP) is a poorly under-
stood disorder characterized by recurrent episodes of
protracted vasospasm on cold exposure (1). The disease
may occur as a primary manifestation (primary RP) or
as part of a constellation of findings in patients with
diverse rheumatologic conditions (secondary RP) (2).
Although abnormalities in endothelial function in con-
duit and resistance vessels and elevations in circulating
vasoconstrictor mediators such as endothelin 1 (ET-1)
have been described (3–5), these findings have not been
consistent (6,7). In addition, the precise etiologic role of
these abnormalities in the pathogenesis of primary RP
versus secondary forms of this disorder is not clear.
Circulating ET-1 levels do not seem to correlate with the
intensity of vasospasm and are not consistently elevated
in RP (8). These differences may stem in part from
studies comparing patient populations with different
levels of disease severity, presence of underlying connec-
tive tissue disease, and concomitant vascular risk factors.
The loss of nitric oxide (NO), the hallmark of
endothelial dysfunction, is an attractive possibility as an
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overall mechanism for the pathogenesis of RP, since
perturbations in the NO pathway may have pleiotropic
effects on multiple effector pathways that may be rele-
vant in RP, including ET-1 (9). In this regard, although
abnormalities of both conduit and microvascular endo-
thelial function have been demonstrated in RP, the
contribution of these 2 levels of circulation in explaining
the differential features in primary and secondary RP
requires further definition (3,4,10,11). Recently, a novel
circulating endogenous inhibitor of endothelial nitric
oxide synthase (eNOS), called asymmetric dimethylargi-
nine (ADMA), has been described (12). ADMA is
synthesized in human endothelial cells and is believed to
alter eNOS function in many ways, including inhibition
of function, increases in endothelial oxidative stress, and
alterations in substrate binding (13).
We hypothesized that individuals with RP sec-
ondary to connective tissue diseases, when compared
with subjects with primary RP, have heightened sensi-
tivity of upper extremity conduit and resistance vessels,
and that these changes are correlated with increases in
ET-1 and ADMA. The present study was undertaken to
test this hypothesis.
PATIENTS AND METHODS
Study subjects. The Institutional Review Board at the
University of Michigan approved the study protocol. Subjects
were screened and recruited in a prospective manner through
advertisements in the University of Michigan rheumatology
outpatient clinic and in the Ann Arbor/Detroit area. The study
was performed during winter months to minimize seasonal
effects on the severity and frequency of episodes. Diagnosis of
RP involved a structured interview assisted by color charts, as
previously described (14), to improve the reliability of the
diagnosis. The following information was collected during the
screening visit: demographic variables, including sex, age,
occupational history, ethnicity, exposure to vibrating tools,
chemicals, and dusts, use of medications, and association with
other vasospastic syndromes (migraine, variant angina). In
addition, information on history of cold injury, polyvinyl
chloride exposure, thoracic outlet syndrome, or crutch pres-
sure was obtained. Characteristics of RP, including the fre-
quency and duration of attacks, number of fingers involved,
associated subjective symptoms (numbness, tingling, pain),
triggering factors, and age at onset, were collected. A clinical
evaluation was performed that included a medical history with
an emphasis on detecting RP-associated diseases. Capillary
microscopy was performed to detect nailfold capillary abnor-
malities related to underlying rheumatologic conditions. Fi-
nally, screening laboratory tests were performed, including
determinations of the levels of serum creatinine, blood urea
nitrogen, and serum lipids (total cholesterol, triglycerides,
high-density lipoprotein, and low-density lipoprotein [LDL]).
Patients with a diagnosis of RP, either primary or
secondary, were included. Diagnosis of primary RP was per-
formed using the following criteria: definite history of episodic
attacks of digital pallor or cyanosis, no evidence of peripheral
vascular disease, no evidence of digital ulcerations, pitting, or
gangrene, normal nailfold capillaries as determined using the
method described by Maricq and Weinrich (14), and negative
results on antinuclear antibody and anti–topoisomerase I tests.
Patients with secondary RP met criteria for other
rheumatologic conditions, including progressive systemic scle-
rosis (SSc) (15), systemic lupus erythematosus (SLE) (16),
primary Sjögren’s syndrome (primary SS) (17), polymyositis/
dermatomyositis (18), rheumatoid arthritis (RA) (19), mixed
connective tissue disease (MCTD) (20), and undifferentiated
connective tissue disease (UCTD) (21). No patients were in
clinical remission. UCTD was diagnosed in patients presenting
with autoimmunity features but who did not fulfill the classi-
fication criteria for a definite connective tissue disease (21).
Patients were excluded from participating in the study if they
had congestive heart failure or documented ejection fraction
40%, uncontrolled hypertension (blood pressure 160/100),
uncontrolled hyperlipidemia (cholesterol 200 mg/dl), diabe-
tes (fasting glucose 100 mg/dl or glycosylated hemoglobin
8%), renal failure (creatinine 2.0 mg/dl), or hepatic failure.
Patients were also excluded if they were current smokers, if
they were taking 2 medications for hypertension, if they were
receiving lipid-lowering therapy, or had recently (within the
previous 4 months) begun treatment with an angiotensin-
converting enzyme inhibitor or angiotensin-receptor blocker.
Postmenopausal women, pregnant women, or women who
were breastfeeding were excluded, as were patients with active
cardiac, central nervous system, or pulmonary disease.
Estimation of attack severity and frequency of epi-
sodes. We attempted to recruit subjects with attacks of roughly
similar severity (22). After vascular responses had been tested
and blood had been obtained as described below, subjects were
followed up in a prospective manner over a 6-week period
during which they were given biweekly symptom diaries, color
charts, and a small pocket notebook with daily attack cards that
had been used in other RP studies, which summarized the
number, severity, and duration of attacks, and the coping
strategies undertaken by the subject (23). Participants were
instructed to keep attack cards at all times, together with color
charts to identify exact color changes of the fingers experi-
enced daily, throughout the 6 weeks of followup. The attack
incidence was calculated as the number of attacks divided by
the number of days of followup. Severity of RP was assessed by
a scoring system. Lack of an attack was scored as 0. If an attack
occurred, the severity was assessed using a previously de-
scribed and validated ordinal system (23) that ranked the
severity on a scale of 1–9. The intrasubject mean for this
parameter over the duration of the study incorporating multi-
ple attacks was calculated. To integrate the frequency and
severity of attacks into a single summary measure, a composite
score was calculated for each subject, based on an area under
the curve (AUC) approach. For each subject, the elapsed time
(in hours) between attacks was multiplied by the severity score
corresponding to the attack at the end of the given time
interval. The intrasubject mean for this composite score was
then determined.
Vascular studies. All studies were conducted between
8:00 AM and 12:00 noon in a darkened, temperature-controlled
room, with the temperature set at 68°F. Studies were per-
formed after an overnight fast.
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Brachial artery vasoreactivity studies. Flow-mediated
dilation (FMD%) of the brachial artery and nitroglycerin-
mediated dilation (NMD%) were determined from
2-dimensional ultrasound images according to established and
validated methodology (24,25). Images were obtained with a
10-mHz linear array transducer and an Image Point ultrasound
system (Hewlett Packard, Andover, MA). Triggered events
(occurring after the peak of the R wave on the electrocardio-
gram) were recorded and acquired through a frame grabber
attached to a computer. Each triggered event consisted of 6
sequential frames. The media–adventitia interface in a linear
portion of the vessel was chosen for analysis.
Laser Doppler studies. Laser Doppler studies were
performed with the Lisca laser Doppler imager (PIM II
system; Lisca, Linköping, Sweden) on the nondominant hand
10 minutes after FMD% studies. Briefly, a cuff was applied to
the subject’s nondominant forearm. The hand and middle
finger were taped flat in the prone position to an examination
table. After positioning the laser beam 15 cm above the center
of the proximal phalanx of the middle digit, baseline measure-
ments were obtained over 2 minutes (Doppler wavelength 670
nm). Baseline perfusion was expressed in perfusion units as the
mean of 6 measurements. Each measurement was performed
over 960 msec in an area measuring 16 mm2. The cuff was then
inflated to a pressure that was 50 mm Hg above the subject’s
resting systolic blood pressure and held for 4 minutes, at the
end of which the pressure was released and serial laser
Doppler scans were obtained immediately upon release for a
total of 6 minutes following release. Reactive hyperemia
measures were expressed as AUC of perfusion measurements
(adjusted for baseline) obtained over a 4-minute period, time
to peak response (the time to attain maximal cutaneous
perfusion in seconds), peak perfusion ratio, which is the peak
perfusion value obtained with reactive hyperemia divided by
baseline perfusion units (arbitrary units), and percent reactive
hyperemia, which was calculated as ([peak perfusion  base-
line perfusion]/[baseline perfusion])  100. Reproducibility of
our brachial artery studies and laser Doppler studies has been
reported previously (26–28).
Cold pressor test (CPT). The CPT was performed by
immersing the nondominant hand in a jacket surrounded by
crushed ice for 45 seconds (29). Imaging of the brachial artery
was obtained 30 seconds before cold exposure and at 30-
second intervals following cold exposure for 4 minutes. The
responses were expressed as the percentage change in base-
line diameter and graphed at 30-second intervals for 3.5
minutes (29).
Laboratory measurements and serum and plasma
markers. Blood samples were collected before vascular studies
were performed. Serum and plasma were obtained by centrif-
ugation of whole blood at 3,000g for 10 minutes, and aliquots
were stored at 20°C.
ET-1 determination. The assay for ET-1 was performed
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN). Briefly, a quantitative sandwich enzyme
immunoassay technique was used. A monoclonal antibody to
ET-1 was precoated onto a microplate. Standards and samples
were pipetted into the wells and any ET-1 present was bound
by the immobilized antibody. After washing away any unbound
substances, an enzyme-linked monoclonal antibody specific for
ET-1 was added to the wells. Following a wash to remove any
unbound antibody-enzyme reagent, an enhanced luminol/
peroxide substrate solution was added to the wells. A micro-
plate luminometer was used to measure the intensity of the
light emitted. For ET-1, duplicate readings were averaged for
each standard, control, and sample and subtracted from the
average zero standard relative light units.
Intercellular adhesion molecule 1 (ICAM-1), vascular
cell adhesion molecule 1 (VCAM-1), and monocyte chemoattrac-
tant protein 1 (MCP-1) determinations. Human ICAM-1 and
VCAM-1 were measured from plasma using enzyme-linked
immunosorbent assay kits (R&D Systems), according to the
manufacturer’s directions. MCP-1 levels were detected using a
kit obtained from Endogen (Woburn, MA). The absorbance
was read using a microplate reader (Molecular Dynamics,
Sunnyvale, CA), and a standard curve was generated using a
computer program (SoftPro; Molecular Dynamics). The con-
centration of adhesion molecules and chemokines in each
sample was calculated from the standard curve equation.
Quantification of dimethylarginine derivatives. ADMA
and symmetric dimethylarginine (SDMA) in human plasma
samples were quantified by reverse-phase liquid chromatogra-
phy (Waters, Milford, MA). A 2-pump gradient system (high-
performance liquid chromatography model 510 solvent deliv-
ery system; Waters) delivered 82%–85% (at 27 minutes) to 0%
10 mM sodium acetate trihydrate (pH 4.76) with balance
methanol at 1 ml/minute for 43 minutes. Following precolumn
fluorescent derivatization (AccQFluor; Waters), analyte sep-
aration was performed on a 4.6 mm  250 mm, 3.5 m column
(Xterra MS C18; Waters) with an identical 3.9 mm  20 mm
guard column, both controlled at 36°C (integrated heater-
controller CH-500; Eppendorf, Madison, WI). Standards,
blanks, and samples (10 l) were automatically injected (intel-
ligent sample processor model 712; Waters), and fluorescent
peak height and area were evaluated at an excitation of 250 nm
and an emission of 395 nm (scanning fluorescence detector
model 474; Waters) to original concentrations of 0.1 M.
Statistical analysis. Data management and analysis
were performed using Stata version 6.0 software (Stata Cor-
poration, College Station, TX) and GraphPad Prizm version
3.0 (GraphPad Software, San Diego, CA). Baseline values
were expressed as the mean  SD in the 2 groups of subjects
(primary RP and secondary RP) unless otherwise indicated.
Values for each group were compared using paired 2-tailed
t-tests (  0.05). CPT results were graphed for each group at
30-second intervals from 0 to 3.5 minutes. An aggregate CPT
response using the AUC approach was calculated for subjects
with primary RP and secondary RP, and this was used for
correlation analysis. Correlation analysis was performed be-
tween log-transformed circulating ET-1 levels, ADMA levels,
or an aggregate score of ET-1/ADMA and measures of
microvascular and macrovascular responses and reported as
Spearman’s rank correlations (rs). Univariate and multivariate
analyses using baseline subject characteristics as covariates
were performed. P values less than 0.05 were considered
significant.
RESULTS
Clinical and demographic characteristics. Forty
patients with primary RP or secondary RP were studied.
1994 RAJAGOPALAN ET AL
The baseline demographics of these patients are in-
cluded in Table 1. The majority of patients in both the
primary and secondary RP cohorts were women. The
mean (SD) duration of RP was 10  6 years in the
primary RP population and 12  8 years in the second-
ary RP population. Symptoms in the patients were
moderate to severe, with patients in the primary RP
population reporting a mean (SD) of 2.1  1 vasospas-
tic attacks per day and patients in the secondary RP
population reporting a mean (SD) of 2.4  2 vasospas-
tic attacks per day. Severity scores were comparable. No
patients with RP secondary to occupational hazards or
medications were included in this study. No patients had
evidence of ischemic ulcerations when the study was
performed. There were no significant differences in the
groups of patients with primary and secondary RP with
regard to blood pressure, LDL cholesterol, or adiposity.
The underlying diagnoses in patients with sec-
ondary RP were as follows: SLE (25%), SSc/CREST
syndrome (35%), primary SS (15%), UCTD (10%),
polymyositis (5%), rheumatoid arthritis (5%), and
MCTD (5%). None of the patients with secondary RP
had evidence of clinical remission. No patients had
evidence of ischemic ulceration or pitting at the time this
study was performed. Of the 2 individuals diagnosed as
having UCTD, 1 had polyarthralgias, RP, and autoanti-
bodies, and the other had hypocomplementemia, ar-
thralgias, and RP.
Vascular responses in primary and secondary
RP. Baseline brachial artery diameters in patients with
primary and secondary RP did not differ (mean  SD
3.51  0.8 versus 3.68  0.08 mm, respectively; P 
0.05). Figure 1 shows flow-mediated dilation in brachial
arteries in response to a reactive hyperemia stimulus.
Median (25th, 75th percentiles) FMD% response at
baseline in patients with primary RP was 3.95 (2.22,
7.36), compared with 2.55 (0.72, 5.60) in the cohort of
patients with secondary RP (P  0.05). Similarly,
NMD% in both groups was comparable (16.22 [13.14,
26.20] in patients with primary RP and 19.55 [12.79,
24.77] in patients with secondary RP) (Figure 2). CPT
responses of conduit vessels in patients with primary and
secondary RP were determined, and results are shown in
Figure 3. The responses in primary and secondary RP
Figure 1. Flow-mediated dilation (FMD%) in brachial arteries in
patients with primary and secondary Raynaud’s phenomenon. P 
0.05 at all time points. Boxes show the 25th and 75th percentiles;
horizontal lines in boxes show the medians; vertical bars show the
ranges.
Figure 2. Nitroglycerin-mediated dilation (NMD%) in brachial arter-
ies in patients with primary and secondary Raynaud’s phenomenon.
P  0.05 at all time points. Boxes show the 25th and 75th percentiles;
horizontal lines in boxes show the medians; vertical bars show the
ranges.





Age, years 47  12 42  13
Female, no. (%) 14 (70) 15 (75)
White, no. (%) 17 (85) 20 (100)
BMI, kg/m2 24  4 24  6
Systolic blood pressure,
mm Hg
122  21 120  14
Diastolic blood pressure 70  14 72  13
Total cholesterol, mg/dl 205  45 188  41
LDL, mg/dl 120  42 103  30
Duration of RP, years 10  6 12  8
Attack frequency/day 2.1  1 2.4  2
Composite severity
score
100  70 108  83
Mean brachial artery
diameter, mm
3.58  0.70 3.50  0.73
* Except where indicated otherwise, values are the mean  SD. RP 
Raynaud’s phenomenon; BMI  body mass index; LDL  low-density
lipoprotein.
VASOCONSTRICTIVE MECHANISMS IN RP 1995
were characterized by predominant vasoconstriction. No
significant differences were observed at individual time
points or in the aggregate response of conduit vessels to
cold in either group.
We then evaluated cutaneous resistance vessel
function in the 2 cohorts. The responses were quantified
as a cumulative index of perfusion (AUC 4 minutes),
peak perfusion ratio, percent reactive hyperemia, or as
time to peak perfusion. As seen in Table 2, in the group
of patients with secondary RP (but not the group with
primary RP), laser Doppler–derived skin perfusion val-
ues in response to reactive hyperemia were character-
ized by a reduction in AUC responses adjusted for
baseline perfusion, but not in percent reactive hyper-
emia, time to peak response, or peak perfusion ratios
(AUC 183  120 perfusion units in patients with sec-
ondary RP and 815  1,342 perfusion units in patients
with primary RP).
ET-1 and ADMA levels in RP. Circulating ET-1
in patients with secondary RP was elevated compared
with that in patients with primary RP (mean  SD
0.75  0.12 and 0.31  0.07 pg/ml, respectively; P 
0.0183 by Mann-Whitney U test) (Figure 4). Figure 5
shows the levels of ADMA, an endogenous inhibitor of
nitric oxide synthase, in RP. ADMA, but not SDMA,
levels were higher in patients with secondary RP when
compared with patients with primary RP (mean  SD
0.95  0.03 and 0.81  0.06, respectively; P  0.0275 by
Mann-Whitney U test). Finally, as seen in Figure 6,
patients with secondary RP had higher levels of
VCAM-1, ICAM-1, and MCP-1 when compared with
patients with primary RP (P  0.05 for all 3). Correla-
tion analyses were performed for ET-1 and ADMA
against measures of microvascular function and conduit
vascular function in the entire RP population as well as
in the primary and secondary RP groups. ET-1 and
ADMA, when analyzed individually, predicted impair-
ment in microvascular function as measured by the AUC
in both primary and secondary RP. ET-1 levels, when
combined with ADMA levels, correlated significantly
with the AUC measure (rs  0.54, P  0.017). There
was no correlation between increases in ADMA and
brachial artery endothelial function in either primary or
secondary RP. Similarly, when the cumulative response
to CPT in conduit vessels over 3.5 minutes was com-
pared with ADMA and ET-1 levels, there did not appear
to be a significant correlation in either the primary or
secondary RP group.
Compared with RP in other autoimmune dis-
Figure 3. Cold pressor test responses in patients with primary and
secondary Raynaud’s phenomenon. Shown is the percentage change in
brachial artery diameter for 3.5 minutes, at 30-second intervals,
following 2 minutes of ice exposure. Values are the means. P  0.05 at
all time points.
Figure 4. Plasma endothelin 1 levels in patients with primary and
secondary Raynaud’s phenomenon. Values are the mean and SD.  
P  0.02, by Mann-Whitney U test.
Table 2. Laser Doppler–derived skin perfusion values in patients
with primary and secondary RP*
Index Primary RP Secondary RP
Microvascular: baseline
perfusion
0.08  0.1 0.14  0.2
Reactive hyperemia
Peak perfusion ratio 38  65 10  7
Percent reactive hyperemia 3,743  6,474 878  712†
Reactive hyperemia AUC 815  1,342 183  120
Time to peak response,
seconds
30  18 20  15
* Values are the mean  SD. RP  Raynaud’s phenomenon; AUC 
area under the curve; reactive hyperemia AUC  AUC over 4 minutes
of reactive hyperemia response corrected for baseline perfusion.
† P  0.0048 for AUC versus primary RP group, by unpaired t-test.
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eases, RP attacks tend to be more severe in patients with
SSc/CREST. These more frequently result in digital tip
ischemic ulcers, infarcts, and amputations. To exclude
the possibility that the abnormalities found in secondary
RP were attributed only to the SSc/CREST subgroup,
we additionally analyzed patients with SSc/CREST and
individuals with other autoimmune diseases separately.
We found that the differences between primary and
secondary RP in ET-1 and ADMA, as well as AUC
measurements, persisted even after exclusion of the
patients with SSc, who were a small percentage of the
overall secondary cohort.
DISCUSSION
RP as a manifestation of connective tissue dis-
ease is frequent and often precedes other symptoms and
signs (30,31). The manifestations, severity, and progno-
sis of secondary RP are very different from those of
primary RP and include progression to cutaneous ulcer-
ations and tissue necrosis (30,32). Accurate differentia-
tion of secondary RP from primary RP is partly depen-
dent on identification of pathophysiologic mechanisms
and vascular abnormalities that are unique to these two
disease states. To achieve this, comparisons of primary
and secondary RP at relatively similar degrees of sever-
ity is important, because variations of disease severity
and concomitant vascular risk factors may complicate
the interpretation of observations (33).
Accordingly, the main objective of this study was
to compare and contrast microvascular and macrovascu-
lar abnormalities in a cohort of patients with primary
and secondary RP who were carefully matched for
demographic, LDL, hemodynamic, and severity profiles.
The main findings of this study were the following: no
differences in endothelium-dependent or -independent
function in conduit vessels between patients with pri-
mary and secondary RP; abnormal vasoconstrictor re-
sponse of brachial arteries to cold in both patients with
primary and those with secondary RP, with no differ-
ences in the intensity of vasoconstriction between pa-
tients with primary and secondary RP; abnormal micro-
Figure 5. Asymmetric dimethylarginine (ADMA) and symmetric
dimethylarginine (SDMA) levels in primary and secondary Raynaud’s
phenomenon. Values are the mean and SD.   P  0.03, by
Mann-Whitney U test.
Figure 6. Adhesion molecule and chemokine expression in patients
with primary and secondary Raynaud’s phenomenon. ICAM-1 
intercellular adhesion molecule 1; VCAM-1  vascular cell adhesion
molecule 1; MCP-1  monocyte chemoattractant protein 1. Values are
the mean and SD.   P  0.05, by Mann-Whitney U test.
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vascular function in patients with secondary RP, but not
patients with primary RP, as evidenced by a blunted
cutaneous response to a reactive hyperemic stimulus;
and increases in circulating ET-1 and ADMA in patients
with secondary RP compared with patients with primary
RP, accompanied by increases in VCAM-1 and MCP-1
levels.
To our knowledge, this is the first study to
compare and contrast vasodilator mechanisms at both
the resistance and conduit levels in primary and second-
ary RP. Our patient population with secondary RP was
a heterogeneous group composed of patients with dif-
ferent connective tissue diseases that can present with
RP symptoms. These individuals were compared with a
cohort of patients with primary RP who were otherwise
matched for disease severity and risk factors known to
modulate vascular function. Indeed, blood pressure,
LDL cholesterol, and adiposity were identical in the 2
groups. Conduit endothelial function and endothelium-
independent function in our study, as determined by
reactive hyperemia and responsiveness to cold in the
brachial artery, did not differ between the 2 cohorts.
However, both primary and secondary RP were charac-
terized by abnormal vasoconstrictor responses to cold as
opposed to the normal vasodilator response, reiterating
abnormal sympathetic outflow at the vessel wall in this
disease (34).
In contrast to the homogeneity of responses of
conduit vessels in patients with primary and secondary
RP, there was an impairment of microvascular responses
in patients with secondary RP compared with patients
with primary RP, as evidenced by a diminution in
reactive hyperemic flow over time, adjusted for baseline
perfusion. In our experience, AUC measurements,
which represent a composite measurement over time,
were superior to single-point measurements such as
peak perfusion ratio and percent reactive hyperemia or
time to peak. Consistent with prior studies, we demon-
strated an increase in circulating ET-1 levels in patients
with secondary RP compared with patients with primary
RP (5,35).
A novel finding in this study was the demonstra-
tion of elevation of a circulating endogenous inhibitor of
NOS, ADMA, in patients with secondary RP compared
with patients with primary RP. ADMA has been previ-
ously reported to be elevated in a variety of conditions
associated with attenuation of arterial vasodilator re-
serve, including atherosclerosis and hypercholesterol-
emia (12,36). In these conditions, ADMA levels are only
elevated 0.5–3-fold above the normal concentrations.
Thus, the range of values noted in these conditions is
fairly small. Previous studies have shown that exogenous
concentrations between 1 and 10 M/liter affect
endothelial-dependent vasodilation in rat mesenteric
and cerebral vessels (37,38). Similarly, incubation of
cultured endothelial cells with oxidized LDL results in
increases of ADMA from 0.6 M/liter to 1.1 M/liter at
the end of a 48-hour period (39). Thus, ADMA levels
are tightly regulated and the levels reported are likely to
be of pathophysiologic significance. Both ADMA and
ET-1, either alone or potentially together, can modulate
resistance vessel function (40,41).
In this regard, previous studies in experimental
heart failure have shown that ET-1 stimulates ADMA
(42), and our studies confirm a connection between the
ET-1 axis and ADMA in the RP population. Inhibition
of NOS in the skin with inhibitors such as L-NG-
nitroarginine methyl ester can potentiate the effect of
ET-1–mediated vasoconstriction, and thus these two
mediators can potentially act together (43). Increases in
ET-1 are well known to interact negatively with the NOS
pathway and, together with elevations in ADMA, could
represent a potent vasoconstrictor combination that sets
the stage for progression of vascular disease and its
complications. Indeed, ET-1 and ADMA levels taken
together significantly correlated negatively with micro-
vascular perfusion. Thus, it may be argued that the
vascular abnormalities observed in patients with RP are
unlikely to be affected by targeting one pathway alone.
Since ADMA has been reported to be increased
in patients with renal failure and hypercholesterolemia,
it is important to mention that none of the patients
studied had renal dysfunction (creatinine 1.4 mg/dl) or
elevations in LDL cholesterol (44). As expected, an
inactive structural isomer of ADMA, SDMA, was not
elevated in patients with secondary RP, supporting the
accuracy of our ADMA analysis by high-performance
liquid chromatography. Although increases in ET-1 and
ADMA were negatively correlated with changes in mi-
crovascular flow, they did not correlate with conduit
endothelial function (FMD%) or responses to cold in
patients with either primary or secondary RP. This
finding may relate to the fact that once other traditional
risk factors that more directly correlate with conduit
endothelial function (such as LDL cholesterol) are
accounted for, conduit responses in RP are comparable,
despite differential elevations of ADMA and ET-1.
Thus, differences in microvascular flow may represent
an inherent susceptibility of the cutaneous resistance
circulation to these mediators in patients with secondary
RP.
Previous studies have shown that ET-1 release
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and expression are linked to alterations in chemokine
and adhesion molecule expression (45,46). Our findings
reaffirm and extend these observations linking the in-
flammatory cytokine network with the neurohormonal
system, which may promote peripheral inflammation
and oxidative stress in the cardiovascular system of
patients with connective tissue disease and RP. The
elevation of MCP-1 and VCAM-1 in patients with
secondary RP may reflect the unfavorable effects of
dysfunctional NOS and ET-1 pathways in patients with
RP and indicate early activation of a proinflammatory
process in the vasculature of patients with secondary RP.
These findings add to evidence from prior studies dem-
onstrating that patients with different connective tissue
diseases associated with secondary RP have increased
VCAM-1, ICAM-1, and MCP-1 levels, and that their
levels in plasma correlate with their in situ expression
(47).
In conclusion, both primary and secondary RP
are characterized by abnormal conduit vessel vasocon-
striction to cold. Secondary RP is also associated with
attenuation of microvascular responses to reactive hy-
peremia and elevations in ADMA and ET-1. Increases
in these vasoactive mediators acting together in patients
with secondary RP may influence alterations in vascular
function and proinflammatory pathways, and therefore,
disease progression.
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